GRAIL announced that the FDA's advisory panel will meet on September 23, 2026, to review the Premarket Approval application for its Galleri blood test, designed to detect multiple cancers early by identifying cancer-specific methylation patterns. The test aims to detect cancers before symptoms appear, including those without current recommended screenings, and to predict the cancer's origin to guide diagnosis. GRAIL highlights that Galleri is supported by large clinical studies showing increased cancer detection with low false positives and is intended to complement existing screening methods. The FDA designated Galleri as a Breakthrough Device in 2018, and the review marks a significant step toward potentially transforming cancer screening in the U.S.
XRP's market capitalization has surged past $94 billion, exceeding Belarus' estimated 2025 GDP of $93.4 billion. This milestone highlights XRP's rapid growth, also surpassing the market cap of major financial firm Intercontinental Exchange. Meanwhile...
Bitcoin surged past $79,000 after breaking a six-week range, driven by strong spot demand and $1.92 billion inflows into U.S. spot Bitcoin ETFs over five days. This rally, supported by short-term holders reclaiming cost bases near $68,500 and a $3 bi...
Micron Technology is expected to see a modest stock price increase of about 1.4% by September 1, 2026, reaching an average price of $980. This forecast is based on a machine learning model combining multiple AI tools and technical indicators. The com...
Michael Saylor reaffirmed his view of Bitcoin as digital economic energy that can be securely controlled by individuals, companies, or governments. Strategy, the company he leads, holds 840,447 Bitcoin, about 4% of the total supply, valued at $64.86 ...
Solana's real-world asset (RWA) ecosystem surpassed $4 billion in total value for the first time in August 2026, nearly tripling from $1.4 billion in January. This growth was steady, with $263 million in net inflows over 30 days, contrasting Ethereum...
